Scott Rocklage Works with Expansion Therapeutics

Even though there may be individual effort involved in the turning of a vision into reality, endeavors that truly benefit mankind as a whole require teamwork. Expansion Therapeutics knows this matter of fact as a truth, through bringing together Series A financing into a portfolio designed to combat ailments based on genetics. At the top of the list of ailments to push back is Myotonic Dystrophy type I, which also goes by the name DM1.


This disorder is a major and leading cause for Muscular Dystrophy in adults, caused by RNA that have reached toxic levels. To reach its collective goal, Expansion Therapeutics continues to seek and manage financial resources to the tune of more than 50 million dollars. The collaborative effort of Expansion Therapeutics includes Sanofi Ventures, Kleiner Perkins, Novartis Venture Fund and 5AM Ventures all working together to end genetic disorders like DM1. This effort enjoys an assist from Alexandria Venture Investments and RA Capital Management.


The breakthroughs these organizations seek to make are based on the RNA molecules found in cells. DM1 and the ailment it causes effects the central nervous, hormonal, respiratory and gastrointestinal systems, as well as the heart and range-of-motion muscles. The medication that Expansion Therapeutics produces to treat diseases as a result of defective RNA are most important to patients and their families. This statement is particularly true because collective efforts of the organizations under the Expansion umbrella research expansion repeat disorders, which spread through heredity.


Every team has a set of leaders and key members who bring others together and make reaching the ultimate goal possible. In the case of Expansion Therapeutics, there are two names that stand out and deserve just a bit of notice. The first name to know is Matthew D. Disney Ph.D. who Performs as the main researcher for the scientific team. And while Disney makes sure that progress happens in the lab, 5AM Ventures Managing Partners, Scott M. Rocklage ensures future opportunities for the laboratory. When it comes to getting medications on the market, Rocklage has 30 years of experience to draw from.


Visit to learn more.

Securus Technologies Advanced Drone Detection Technology Defeats the Weakness of Traditional Drone Detection Systems

There has been a growing trend for authorities to find drones flying in unrestricted areas and the problem seem to be growing at a fast pace. With the availability of recreational drones in the market, there have been steps taken to help restrict the use of these drones. But, still, some people defy these rules and use it for illegal activities. Drones can be modified to carry out a specific task. They can carry more than 11 pounds weight that has led to criminals using it has a delivery mechanism for contraband items into the prisons. Thus, drones are becoming a threat to the society by providing the inmates with things that can allow them to create terror outside the prison even though they are locked up.


Over the years, there have been different drone detection system in the market, but these are not as useful today. Some of these systems used the sound of the drone to detect it while others used cameras to help catch any drone flying over the restricted area. Some more advanced technology such as radar and thermal detection system was also tried but to no vain. They too did not pick up drones as efficiently and stopping them is not always successful. Securus Technologies has been working on a drone detection technology that is not just efficient but also foolproof.


Securus Technologies has already been testing their new technology that would help not just identify any drone nearby, but also provide the coordinate of the drones to help catch it. It also provides additional data of the drone and also helps find the operator that might be miles apart. There is more significant awareness among drones among the prison industries, and it is the reason why drone detection technology by Securus Technologies is in high demand.



The Basis Supplement and Your Health

Elysium Health

Elysium Health is a health startup co-founded in 2014 by Dr. Leonard Guarente. Dr. Guarente has conducted significant research on the molecular and genetic causes of aging during his career. Dr. Guarente is also the director of the Paul F. Glenn Laboratory for Biology  of Aging Research at MIT, in addition to being the founder and chief scientist of Elysium Health.

Elysium Health translates advances in science and technology to create clinically-validated health supplements that work.

The Supplement Basis

Based on more than 25 years of prior research, Elysium Health sells a supplement called Basis. Nicotinamide riboside and pterostilbene are the two ingredients that make up Basis. Taken together, the two increase levels of NAD+ in our cells. NAD+ is a coenzyme that is essential to hundreds of our cellular functions, including circadian rhythms, energy creation, and DNA protection. As we age, our levels of NAD+ decline and those functions break down.

Elysium Health decided to put Basis through a clinical trial in order to ensure its effectiveness. The trial demonstrated  that taking the recommended daily dose of Basis over the course of several weeks increased levels of NAD+ by an average of 40 percent in humans.

Elysium Health sells Basis on its website  in a variety of monthly subscriptions, as well as in individual jars. Each jar contains 60 capsules (the recommended daily intake is two capsules). A regular month-to-month subscription costs $50 each month. The most popular plan is the six-month subscription to Basis for $270, which breaks down to $45 per month. They also sell a one-year subscription for $480, or $40 per month.

Visit Elysium Health’s website for more information about the company, its team of scientists, and the science behind Basis.

Luiz Carlos Trabuco Cappi, To Step Down After Almost 20 Years As Bradesco President

The banking and finance giant Bradesco will be replacing its current president Luiz Carlos Trabuco Cappi and introducing its new president Octavio de Lazari Junior during the upcoming AGO meeting scheduled for March 12th 2018. Luiz Carlos Trabuco Cappi announced other changes at the executive level effective in next few weeks. There are change to vice president position, and Lazaro Brandao has handed in his letter of resignation.

Bradesco’s current president Luiz Carlos Trabuco Cappi was appointed to be the 4th president since its was founded in 1943. Bradesco was founded in the city of Marilia, the same place Luiz Carlos Trabuco Cappi was born. Luiz Carlos Trabuco Cappi was a bank clerk for Bradesco back in 1969. A short three years later Luiz Carlos Trabuco Cappi moved to Sao Paulo. Luiz Carlos Trabuco Cappi became the Director of Marketing in 1984. As Marketing Director, Luiz Carlos Trabuco Cappi realized the need for a better relationships with the press on the transparency of the daily activities of Bradesco, and changed the culture of the company’s approach to public relations. Luiz Carlos Trabuco Cappi was named Executive Director and President of Bradesco’s pension division, a position he held from 1992 to 1998. Luiz Carlos Trabuco Cappi, a year later was promoted to Vice President of Bradesco, and until 2005 he was also a Chief Executive. The process of selecting a new president was one Bradesco was not going to rush, thus Lazaro Brandao prolonged the age restriction of 65 to 67, giving the company more time to go through the selection process. Bradesco recently bought HSBC, and this was another crucial factor in deciding not to rush this process. Despite the incoming president’s qualifying credentials, his appointment was still meet with some disapproval, shared Luiz Carlos Trabuco Cappi. Luiz Carlos Trabuco Cappi went on to say the bank stands behind Octavio de Lazari Junior as the new president.


Octavio de Lazari Junior, has an Graduates degree in economics, he earned from attending Faculty of Economics and Administrative Science of Osasco. Octavio de Lazari Junior also has a specialization in Financial Strategies and Marketing from Fundacao Instituto de Administracao. Starting at Bradesco back in 1978, and he quickly advanced to become an agency manager. Octavio de Lazari Junior was promoted in 2010 as the Department Director of Loans and Financing. Octavio de Lazari Junior in 2012 be appointed to the Board of Directors Officers and as of 2017 Octavio de Lazari Junior became the Executive Officer and Vice President of Bradesco Seguros Group. Octavio de Lazari Junior is also the Director of Real Estate Credit and Savings and he is the Vice President of Febraban’s Credit.

Carlos Alberto Rodrigues Guilherme will be taken the vice presidency, with the stepping down of Luiz Carlos Trabuco Cappi. Carlos Alberto Rodrigues Guilherme began working at only 13 years for Bradesco.

The new president Octavio de Lazari Junior will be faced with challenges as revealed by Luiz Carlos Trabuco Cappi, but he is confident Octavio de Lazari Junior capabilities as a leader.

Search more about Luiz Carlos Trabuco Cappi:,bradesco-anuncia-substituto-de-luiz-trabuco-na-presidencia-do-banco,70002178384